February 4, 2026 4:37pm

Another share pricing beat-down: Cause, upcoming C&GT sector earnings, the Ai trade bottoms, tech earnings, index fluctuations, ADP falling short of expectation; with multiple effects … markets and the C&GT sector

As I wrote this a.m., “Rotations and tech sell-offs still a problem”. Right again, I just at it!

News: MiMedx Group (MDXG +$0.14) has entered into an exclusive agreement with Summit Products Group to distribute 3 innovative, 510(k) cleared Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plus.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Wednesday’s RMi Pre-opening: Tug-of-pricing … https://www.regmedinvestors.com/articles/14297

RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719 … https://www.regmedinvestors.com/articles/14295   

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The Dow closed UP +259.91 points or +0.53%, the S&P closed DOWN -35.06 points or -0.51% while the Nasdaq closed DOWN -350.606 points or -1.51%

  • Theme of the session: the real question, where is the immediate and near-term “satisfaction” from Ai as momentum slides

Wednesday’s (my) 40-company covered sector’s advance/decline line opened negative with 9 incliners, 30 decliners and 1 flat, ending with a barely negative close of 10 incliners, 29 decliners and 1 flat

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Payroll giant ADP reported that employers in the private sector added just 22,000 jobs in January, about half the size of the 45,000-job gain economists were expecting. Job growth slowed further from December’s employment gains that were revised down to 37,000 from 41,000.           
  • January’s job gains were driven entirely by continued hiring in the education and health services industry, which added an estimated 74,000 jobs, ADP’s report showed. Health care, which is growing as a result of an aging population, has been one of the few industries to have experienced consistent employment expansion in recent years.
  • The Institute for Supply Management said that growth for health care, construction and other U.S. services businesses continued in January at the same pace that economists expected. It also indicated that prices paid by U.S. services businesses rose at a faster rate in January, which could be a discouraging signal for inflation.

The CBOE Fear (VIX) index, Wednesday closed at 19.25, after Tuesday’s 17.91, Monday’s 16.53, Friday’s 17.66, Thursday’s 16.89 and last Wednesday’s 16.40

Metrics: Wednesday …

  • The RUT was down -23.95 points or -0.90%,
  • The XLV was up +1.93 points or +1.25%,
  • The NBI was up +14.53 points or +0.25%;
  • The XBI was down -2.36 points or -1.85%
  • The IWM was down -2.21` or -0.84%;
  • The IBB was up +0.25 points or +0.14%,
  • The VIX was up +1.25 points or +6.94% at to 19.25

 

Q1/26 February – 2 negative and 1 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 10) 

  • Vertex (VRTX +$4.91 after Tuesday’s -$6.40 after Monday’s +$2.11),
  • Supernus Therapeutics (SUPN +$0.68 after Tuesday’s -$0.38 after Monday’s +$0.62),
  • Moderna (MRNA +$0.57 after Tuesday’s -$0.35 after Monday’s -$1.52),
  • BioNTech (BNTX +$0.52 after Tuesday’s -$0.63 after Monday’s -$4.87),
  • Ionis Pharmaceuticals (IONS +$0.40 after Tuesday’s +$1.52),
  • Alnylam Pharmaceuticals (ALNY +$0.16 after Tuesday’s +$12.69 after Monday’s +$1.05),
  • MiMedx (MDXG +$0.14),
  • Caribou Biosciences (CRBU +$0.06),
  • Cellectis SA (CLLS +$0.01 after Tuesday’s -$0.29),
  • Brainstorm cell Therapeutics (BCLI +$0.01),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Tuesday’s $0.00 (was -$0.11) after Monday’s -$0.10 after Friday’s $0.00)

Wednesday’s Closing DOWN (10 of 29): 

  • Arrowhead Pharmaceuticals (ARWR -$4.08 after Tuesday’s -$0.86 after Monday’s +$3.67 ),
  • CRISPR Therapeutics (CRSP -$1.83 after Tuesday’s +$0.69 after Monday’s +$1.35 ),
  • IQIA Holdings (IQV -$1.48 after Tuesday’s -$27.54 after Monday’s +$1.01),
  • uniQure NV (QURE -$1.15 after Tuesday’s +$3.10 after Monday’s +$1.98),
  • AxoGen (AXGN -$0.99 after Tuesday’s +$0.19),
  • Entrada Therapeutics (TRDA -$0.97),
  • Beam Therapeutics (BEAM -$0.94),
  • Lenz Therapeutics (LENZ -$0.91 after Tuesday’s -$0.77),
  • Dyne Therapeutics (DYN -$0.73 after Tuesday’s +$0.20 after Monday’s +$0.87)
  • Intellia Therapeutics (NTLA -$0.69),

 

The Bottom Line: More of the … WHY

New month, another sprint down after Monday’s big up …

U.S. equity markets were mixed on Wednesday as investors weighed soft labor data against earnings reports from tech and pharma companies.

  • Even better-than-expected earnings are no longer enough to convince the market, unless the company reporting can show that AI will be a tailwind rather than a headwind.

In a sign of cracks in the labor market, an ADP report showed employers added just 22,000 jobs in January, versus the 45,000 expected.

  • Private data has taken on outsized importance amid the delay in federal jobs data from the partial government shutdown that ended Tuesday, as the Bureau of Labor Statistics has rescheduled the official jobs report for next Wednesday. <Yahoo Finance>

Macro healthcare:

  • Eli Lilly (LLY) rallied 9.5% after topping analysts’ expectations for profit in the latest quarter. It’s been riding big growth created by its Mounjaro and Zepbound products for diabetes and weight loss.
  • Amgen (AMGN) surged 6% after reporting better-than-expected earnings and revenue for the Q4.
  • Novo Nordisk (NVO, NOVO-B.CO) after the maker of Ozempic and Wegovy shocked investors by forecasting a steep drop in sales.

 

Since, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

•              2/5 – Arrowhead Pharmaceuticals (ARWR)

•              2/5 – IQVA Holdings (IQV)

•              2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX)

•              2/13 – Moderna (MRNA)

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

•              As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 1st week

  • Wednesday closed negative with 10 incliners, 29 decliners and 1 flat        
  • Tuesday closed negative with 18 incliners, 21 decliners and 1 flat
  • Monday closed positive with 29 incliners, 10 decliners and 1 flat

January – 5th week:

  • 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
  • 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
  • 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: Vertex (VRTX), Supernus therapeutics (SUPN) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Capricor Therapeutics (CAPR)
  • Monday: Arrowhead Pharmaceuticals (ARWR), Vertex (VRTX) and UniQure NV (QURE)
  • Friday: Arrowhead Pharmaceuticals (ARWR), AxoGen (AXGN) and Brainstorm Cell Therapeutics (BCLI)

The worst three (3) in the session: Losers

  • Wednesday: Arrowhead Pharmaceuticals (ARWR), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and Regenxbio (RGNX)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.